Climb Bio, Inc. (CLYM)
10.29
+1.42
(+16.01%)
USD |
NASDAQ |
Nov 06, 16:00
10.25
-0.04
(-0.39%)
After-Hours: 20:00
Climb Bio Research and Development Expense (Annual) : 46.62M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 46.62M |
| December 31, 2024 | 11.61M |
| December 31, 2023 | 15.41M |
| December 31, 2022 | 26.21M |
| Date | Value |
|---|---|
| December 31, 2021 | 23.32M |
| December 31, 2020 | 18.50M |
| December 31, 2019 | 6.769M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Korsana Biosciences, Inc. | 0.959M |
| Cullinan Therapeutics, Inc. | 187.40M |
| Q32 Bio, Inc. | 19.16M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |